What dilution and infusion duration should be used for durvalumab (10 mg/kg) intravenous administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Durvalumab Administration: Dilution and Infusion Duration

Durvalumab 10 mg/kg should be diluted and administered as an intravenous infusion over 60 minutes, given every 2 weeks. 1

Preparation and Administration

Dilution Requirements

  • Must be diluted before use - durvalumab cannot be administered undiluted 1
  • The drug comes as a 50 mg/mL concentration (available as 120 mg/2.4 mL or 500 mg/10 mL single-dose vials) 1
  • Dilute in appropriate IV solution per standard institutional protocols for monoclonal antibodies

Infusion Duration

  • Standard infusion time: 60 minutes 1
  • This 60-minute duration applies to all doses and is consistent across indications

Dosing Schedule Options

For patients weighing ≥30 kg, two FDA-approved dosing regimens exist:

  1. Weight-based dosing: 10 mg/kg IV every 2 weeks (original approval) 2, 3, 4
  2. Fixed dosing: 1500 mg IV every 4 weeks (approved November 2020) 5, 6

Both regimens are equivalent in efficacy and can be used for up to 12 months in the consolidation setting for stage III NSCLC 5, 2.

Important Safety Considerations

Infusion Reaction Management

While durvalumab has a relatively low incidence of infusion reactions (IRs), the ESMO guidelines for anti-PD-L1 agents like atezolizumab (a similar agent) recommend 7:

  • No routine premedication required
  • For Grade 1/2 reactions: Stop or slow the infusion rate, provide symptomatic treatment
  • For Grade 3/4 reactions: Stop the infusion permanently and provide aggressive symptomatic treatment

Storage and Handling

  • Store at 2°C to 8°C (36°F to 46°F) 1
  • Do not freeze or shake
  • Keep vial in original carton to protect from light
  • Discard unused portion from single-dose vial

Clinical Context

The 60-minute infusion duration is standard across the durvalumab clinical trial program, including the pivotal PACIFIC trial for stage III NSCLC 2 and studies in other malignancies 3, 4. Real-world evidence confirms this infusion duration is well-tolerated in community practice settings 6.

The every 4-week fixed dosing regimen (1500 mg) offers equivalent outcomes with improved convenience compared to the every 2-week schedule, with similar treatment duration and completion rates in real-world practice 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.